Avanos Medical is acquiring OrthogenRx for $160 million. The company is developing drugs for pain management in osteoarthritis of the knee. Avanos Medical will pay $130 million and another $30 million upon reaching certain milestones in the development of its GenVisc 850 and TriVisc drugs. The deal is scheduled to close in Q1 2022.
Avanos Medical is acquiring OrthogenRx for $160 million. The company is developing drugs for pain management in osteoarthritis of the knee. Avanos Medical will pay $130 million and another $30 million upon reaching certain milestones in the development of its GenVisc 850 and TriVisc drugs. The deal is scheduled to close in Q1 2022. 
avanos.investorroom.com
English (US) 